DDInter947 DDInter1607
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipilimumab
Ipilimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may lead to a major life threatening interaction when taken with {v} Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stanozolol
Stanozolol {u} may lead to a major life threatening interaction when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Larotrectinib {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Lopinavir and Lopinavir (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol and Stanozolol may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) resembles Ritonavir (Compound)